Baxter International, Inc. (NYSE:BAX)
The Company provides medical products and services. Its medical devices, pharmaceuticals and biotechnology assists healthcare professionals and their patients in the treatment of complex medical conditions.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
usubanas
(99.51)
Submitted: 5/1/2013 11:00:07 AM :
Start Price:
$69.80
BAX Score:
-0.39
Gammagard for Alzheimers
Recs
IfHeDiesHeDies
(43.83)
Submitted: 4/8/2013 7:22:23 PM :
Start Price:
$70.29
BAX Score:
-2.91
A+ buy on dips.
Recs
Jolon
(< 20)
Submitted: 1/12/2013 10:12:24 PM :
Start Price:
$68.51
BAX Score:
-7.19
Baxter has solid p/e and I predict it has a bright future ahead
Recs
Marlonito9
(< 20)
Submitted: 9/7/2012 9:44:38 PM :
Start Price:
$59.30
BAX Score:
-7.41
It really should specially in the long run. It's inevitable due to natural market direction.
Recs
dj2000a
(92.67)
Submitted: 7/12/2012 1:02:29 PM :
Start Price:
$52.65
BAX Score:
+13.48
Undervalued according to GS
Recs
ryanman000
(90.99)
Submitted: 4/13/2012 7:45:26 PM :
Start Price:
$54.08
BAX Score:
+13.79
Watching this
Recs
Recs
campwt00global
(37.72)
Submitted: 9/6/2011 10:59:17 AM :
Start Price:
$50.27
BAX Score:
-0.04
9/6/2011 BNY port rotate out of OXY to BAX 8/17/2011 at 53.51 can buy today at 52.48
Recs
Recs
Covestor
(< 20)
Submitted: 3/14/2011 3:05:39 PM :
Start Price:
$49.54
BAX Score:
-18.70
Covestor Model Manager SWAN-asset management sold BAX in his Christian Agape Hedged Equity Covestor Model ( http://covestor.com/SWAN-asset-management )
Recs
Chris5038
(< 20)
Submitted: 2/7/2011 9:06:30 AM :
Start Price:
$45.92
BAX Score:
+31.89
Buying new companies
Recs
frankinCA
(< 20)
Submitted: 12/3/2010 3:35:24 PM :
Start Price:
$46.22
BAX Score:
+26.71
It is another beneficiary of the healthcare and is a low cost provider of hospital IV products that are essential. They are very active in discovering a man made blood replacement for emergency uses, and if ever they make the discovery , it will go to the moon, right!
Recs
thenatural24
(56.33)
Submitted: 9/18/2010 9:09:10 AM :
Start Price:
$42.25
BAX Score:
+24.79
I think this is a classic value play (and has a 2.5% dividend to boot). BAX has shown solid earnings growth and FCF, has a history repurchasing shares, and is, in my opinion, temporaily depressed due to a macro slowdown in protein plasma and antibody therapy. This presents a great buying opportunity.
Recs
jncgator
(< 20)
Submitted: 8/22/2010 12:27:41 PM :
Start Price:
$41.77
BAX Score:
-20.13
This stock will eventually turn out in good shape from its recall on infusion pumps, but for now it should return to the 40 dollar per share range
Recs
falcon2382
(30.29)
Submitted: 5/21/2010 11:27:21 PM :
Start Price:
$59.76
BAX Score:
-37.85
Baxter was a shining star for me until April.... I'm going to pick some up in real life now that its dropped down to 40.... Does the market realize this is a Medical Technology conglomerate? And I know they cited the new Health Care Reform as an excuse as to why their revenues will be lower, but I don't get this. If EVERYONE get's insurance now, how does that negatively impact a medical technology supplier? Further, with Health Information Technology being one of the components of the required changes to healthcare, why not jump on that? Maybe the problem is management? Any thoughts? Any reason not to start nibbling at $40 a share?
Recs
lting77
(59.28)
Submitted: 5/17/2010 4:09:33 PM :
Start Price:
$39.51
BAX Score:
+39.34
-one time charge for teva related propofol negligible in the macro view
-continue dominance as hospital supplier
-also good as safe harbor to park money with dividend yield
Recs
Guanxi
(< 20)
Submitted: 5/7/2010 4:07:38 PM :
Start Price:
$43.37
BAX Score:
+24.07
Financials are strong, company is well diversified, located in over 55 countries and on every continent. Good investment.
Recs
stewart8888
(< 20)
Submitted: 5/4/2010 6:11:37 PM :
Start Price:
$42.00
BAX Score:
+30.50
Company has addressed setbacks and stock will preform well over the next 12 months
Recs
sorensk
(< 20)
Submitted: 5/3/2010 1:44:43 PM :
Start Price:
$43.99
BAX Score:
+27.25
I work for Baxter - Could be in for a run, after the recent restating of projected earning and an approx. 15% drop in share price. Some of the updates/expansions to current high selling products should be just about ready for market by Q3 or 4.
Recs
CarterFortune
(< 20)
Submitted: 4/28/2010 11:03:52 AM :
Start Price:
$44.49
BAX Score:
+24.01
After a big then deserved hit, think this company will outpreform market over next several months.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 78 : 1 2 3 4 Next »